光生物调控通过多巴胺信号级联反应抑制小鼠形觉剥夺性近视进展OA

Photobiomodulation therapy(PBMT)has emerged as a promising non-pharmacological physical intervention for myopia control.However,the optimal irradiation parameters and the underlying mechanisms remain to be further clarified.In this study,a form-deprivation myopia(FDM)mouse model was established,and 650 nm PBMT protocols with different power densities were applied to systematically evaluate the inhibitory effect of PBMT on myopia-associated axial elongation.Changes in dopamine(DA)and nitric oxide(NO)levels in the retina were quantified,and the efficacy and safety of long-term PBMT were further assessed.In addition,ex vivo cell experiments were performed to investigate downstream molecular responses to DA.The results showed that PBMT significantly suppressed abnormal axial elongation in FDM mice(P<0.05),with the most prominent effect observed at a power density of 0.25 mW/cm2.PBMT also markedly increased DA and NO secretion in the retinal(P<0.05)in a dose-dependent manner.Long-term PBMT stably inhibited axial elongation during myopia development without significantly affecting axial length in normal mice,suggesting a favorable safety profile.Furthermore,DA upregulated cellular FBJ osteosarcoma oncogene(c-Fos)expression and promoted tissue inhibitor of metalloproteinases(TIMP2)gene expression in retinal pigment epithelial cells,and these effects were attenuated by D1R inhibition,indicating that the DA-D1R-mediated c-Fos/TIMP2 pathway may contribute to PBMT-induced suppression of axial elongation.Collectively,these findings demonstrate that PBMT effectively alleviates myopia progression in FDM mice,potentially by activating retinal DA/NO signaling and modulating molecular networks associated with tissue remodeling,thereby providing experimental evidence for parameter optimization and mechanistic exploration of red-light-based myopia interventions.